MICHAEL MOORE: Open Payments
NPI 1588339923 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$858 in 23 payments from 7 companies in 2025. Trend: 2023 $337 · 2024 $1,584 · 2025 $858
Food & beverage: $749Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $292 |
| E.R. Squibb & Sons, L.L.C. | 8 | $223 |
| Otsuka America Pharmaceutical, Inc. | 3 | $175 |
| Alkermes, Inc. | 3 | $70 |
| Neurocrine BioSciences, Inc. | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 1 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
Products named: COBENFY, UZEDY, ABILIFY MAINTENA, ARISTADA, ABILIFY ASIMTUFII, INGREZZA, HETLIOZ, AUSTEDO XR.
Industry payments across AZ — which companies pay providers there.
